Characteristics of oedema formation induced by N-formyl-methionyl-leucyl-phenylalanine in rabbit skin.
1. The characteristics of N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced oedema formation were investigated in vivo in rabbit skin. 2. FMLP injected intradermally alone induced a small increase in plasma leakage, but marked synergism with prostaglandin E2 (PGE2) in producing oedema responses was observed. In the presence of PGE2, FMLP was equiactive with C5a des Arg and 100-1000 times more active than histamine in terms of permeability-increasing activity. The response to FMLP was not dependent on endogenous histamine release. 3. FMLP-induced responses were of long duration (t1/2 approximately 40-50 min) when compared with bradykinin (t1/2 approximately 4-5 min). 4. The activity of a range of N-formyl peptides in increasing vascular permeability in skin correlated well with their activity as neutrophil stimulants in vitro. 5. Intravenous infusion of zymosan-activated plasma (ZAP) resulted in transient neutropenia and inhibition of oedema formation induced by FMLP and C5a des Arg in the skin. Responses to bradykinin were unaffected by the infusion of ZAP. 6. Intravenous injection of the non-steroidal antiinflammatory drug, ibuprofen, resulted in an inhibition of FMLP-induced, but not histamine-induced, oedema formation. This effect was independent of cyclo-oxygenase inhibition and the drug did not induced neutropenia. 7. Intravenous injection of the microtubule blocking agent colchicine inhibited FMLP-induced oedema formation. Responses to bradykinin were unaffected. When colchicine was administered after intradermal FMLP, subsequent plasma leakage was abolished. 8. The inference that receptors have evolved to bacterial secretions (i.e. FMLP) and products of the interaction of bacterial cell walls with tissue fluid (i.e. C5a des Arg), is consistent with the hypothesis that oedema formation is fundamentally a functional process concerned with regulating microbial lysis and opsonisation in an infected tissue.
Hellewell
P G
PG
Section of Vascular Biology, MRC Clinical Research Centre, Harrow, Middlesex.
Yarwood
H
H
Williams
T J
TJ
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D003078:Colchicine / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004487:Edema / Q000139:chemically induced / Q000503:physiopathology*; D004731:Endotoxins / Q000032:analysis; D006632:Histamine / Q000494:pharmacology; D007052:Ibuprofen / Q000494:pharmacology; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000008:administration & dosage; D011817:Rabbits; D012871:Skin Diseases / Q000139:chemically induced* / Q000503:physiopathology; D015054:Zymosan / Q000494:pharmacology
D001095:Arachidonic Acids; D004731:Endotoxins; D016718:Arachidonic Acid; D009240:N-Formylmethionine Leucyl-Phenylalanine; D006632:Histamine; D015054:Zymosan; D015232:Dinoprostone; D001920:Bradykinin; D003078:Colchicine; D007052:Ibuprofen